Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADHERE: Efgartigimod PH20 SC for CIDP
NCT04281472Phase 2Completed
- Sponsor
- argenx
- Start
- Apr 2020
- Primary completion
- May 2023
- Modality
- Antibody Fragments
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Efgartigimod PH20 SC with Placebo (2 arms). Primary endpoints: Percentage of Participants With Confirmed Evidence of Clinical Improvement (ECI) up to 12 weeks and Time to First Adjusted INCAT Deterioration Compared to Stage B Baseline up to 48 weeks. Started Apr 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT04281472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281472.